These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2497561)

  • 21. Impaired biliary elimination of beta-glucuronidase-resistant "glucuronides" of valproic acid after intravenous administration in the rat. Evidence for oxidative metabolism of the resistant isomers.
    Dickinson RG; Kluck RM; Wood BT; Eadie MJ; Hooper WD
    Drug Metab Dispos; 1986; 14(2):255-62. PubMed ID: 2870903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Markedly increased omega-oxidation of valproate in fulminant hepatic failure.
    Kuhara T; Inoue Y; Matsumoto M; Shinka T; Matsumoto I; Kawahara N; Sakura N
    Epilepsia; 1990; 31(2):214-7. PubMed ID: 2108017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apparent autoinduction of valproate beta-oxidation in humans.
    McLaughlin DB; Andrews JA; Hooper WD; Cannell GR; Eadie MJ; Dickinson RG
    Br J Clin Pharmacol; 2000 May; 49(5):409-15. PubMed ID: 10792197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abnormal metabolism of valproic acid in fatal hepatic failure.
    Kochen W; Schneider A; Ritz A
    Eur J Pediatr; 1983 Oct; 141(1):30-5. PubMed ID: 6416845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gas chromatography/negative ion chemical ionization mass spectrometry and liquid chromatography/electrospray ionization tandem mass spectrometry quantitative profiling of N-acetylcysteine conjugates of valproic acid in urine: application in drug metabolism studies in humans.
    Gopaul SV; Farrell K; Abbott FS
    J Mass Spectrom; 2000 Jun; 35(6):698-704. PubMed ID: 10862121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic profiling of valproic acid in patients using negative-ion chemical ionization gas chromatography-mass spectrometry.
    Kassahun K; Farrell K; Zheng JJ; Abbott F
    J Chromatogr; 1990 May; 527(2):327-41. PubMed ID: 2117614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Penetration of valproate and its active metabolites into cerebrospinal fluid of children with epilepsy.
    Löscher W; Nau H; Siemes H
    Epilepsia; 1988; 29(3):311-6. PubMed ID: 3131137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers.
    Addison RS; Parker-Scott SL; Eadie MJ; Hooper WD; Dickinson RG
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):715-21. PubMed ID: 11214782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concentration-dependent disposition of glucuronide metabolite of valproate.
    Yu HY; Shen YZ
    J Pharm Pharmacol; 2002 May; 54(5):633-9. PubMed ID: 12005358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of L-carnitine supplementation on acute valproate intoxication.
    Murakami K; Sugimoto T; Woo M; Nishida N; Muro H
    Epilepsia; 1996 Jul; 37(7):687-9. PubMed ID: 8681902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination.
    Kumar S; Wong H; Yeung SA; Riggs KW; Abbott FS; Rurak DW
    Drug Metab Dispos; 2000 Jul; 28(7):857-64. PubMed ID: 10859160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valproic acid overdose and L-carnitine therapy.
    Ishikura H; Matsuo N; Matsubara M; Ishihara T; Takeyama N; Tanaka T
    J Anal Toxicol; 1996; 20(1):55-8. PubMed ID: 8837953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10.
    Argikar UA; Remmel RP
    Drug Metab Dispos; 2009 Jan; 37(1):229-36. PubMed ID: 18838507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of carnitine on the metabolism of valproic acid in epileptic patients.
    Sakemi K; Hayasaka K; Tahara M; Sanada Y; Takada G
    Tohoku J Exp Med; 1992 Jun; 167(2):89-92. PubMed ID: 1475789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy.
    Suzuki Y; Itoh H; Abe T; Nishimura F; Sato Y; Takeyama M
    J Pharm Pharmacol; 2011 Jul; 63(7):976-81. PubMed ID: 21635265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valproic acid disposition in epileptic patients during combined antiepileptic maintenance therapy.
    Hoffmann F; von Unruh GE; Jancik BC
    Eur J Clin Pharmacol; 1981; 19(5):383-5. PubMed ID: 6786896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine.
    Kossak BD; Schmidt-Sommerfeld E; Schoeller DA; Rinaldo P; Penn D; Tonsgard JH
    Neurology; 1993 Nov; 43(11):2362-8. PubMed ID: 8232957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of valproate dose on formation of hepatotoxic metabolites.
    Anderson GD; Acheampong AA; Wilensky AJ; Levy RH
    Epilepsia; 1992; 33(4):736-42. PubMed ID: 1628592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy.
    Mimrod D; Specchio LM; Britzi M; Perucca E; Specchio N; La Neve A; Soback S; Levy RH; Gatti G; Doose DR; Maryanoff BE; Bialer M
    Epilepsia; 2005 Jul; 46(7):1046-54. PubMed ID: 16026556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism.
    Kondo T; Kaneko S; Otani K; Ishida M; Hirano T; Fukushima Y; Muranaka H; Koide N; Yokoyama M
    Epilepsia; 1992; 33(1):172-7. PubMed ID: 1733753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.